A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.
The ARF tumor suppressor signals through p53 and other poorly defined anti-proliferative pathways to block carcinogenesis. In a search for new regulators of ARF signaling, we discovered a novel nuclear protein that we named NIAM (nuclear interactor of ARF and MDM2) for its ability to bind both ARF and the p53 antagonist MDM2. NIAM protein is normally expressed at low to undetectable levels in cells because of, at least in part, MDM2-mediated ubiquitination and proteasomal degradation. When reintroduced into cells, NIAM activated p53, caused a G1 phase cell cycle arrest, and collaborated with ARF in an additive fashion to suppress proliferation. Notably, NIAM retains growth inhibitory activity in cells lacking ARF and/or p53, and knockdown experiments revealed that it is not essential for ARF-mediated growth inhibition. Thus, NIAM and ARF act in separate anti-proliferative pathways that intersect mechanistically and suppress growth more effectively when jointly activated. Intriguingly, silencing of NIAM accelerated chromosomal instability, and microarray analyses showed reduced NIAM mRNA expression in numerous primary human tumors. This study identifies a novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2-p53 signaling.
Pubmed ID: 17110379 RIS Download
Adenocarcinoma | Ancrod | Animals | Breast Neoplasms | Cell Division | Cell Line, Tumor | Cell Nucleus | Chromosomes | DNA-Binding Proteins | Fibroblasts | Humans | Intracellular Signaling Peptides and Proteins | Mice | Molecular Sequence Data | Nuclear Proteins | Osteosarcoma | Proto-Oncogene Proteins c-mdm2 | RNA, Messenger | Tumor Suppressor Protein p14ARF | Tumor Suppressor Protein p53 | Ubiquitin